Takeda N, et al. - Given gastroesophageal reflux disease represents a significant cause of chronic cough, researchers assessed the impacts of anti-reflux treatment as well as its links with cellular and neurogenic inflammation. Participants were 37 patients with suspected GER-associated cough. In a prospective, observational manner, participants were given a proton pump inhibitor, rabeprazole 20 mg daily, and a prokinetic agent, itopride 50 mg t.i.d. for 4 weeks. Significant improvement in the cough visual analog scale, the Japanese version of the Leicester Cough Questionnaire, and acid-reflux symptoms was noted after anti-reflux treatment. Overall, a possible link between successful treatment of GER-associated cough and reduction of neurogenic and neutrophilic inflammation was suggested in this study.